InvestorsHub Logo
Followers 21
Posts 3575
Boards Moderated 0
Alias Born 12/18/2019

Re: ATLnsider post# 459004

Tuesday, 04/12/2022 1:14:21 AM

Tuesday, April 12, 2022 1:14:21 AM

Post# of 708744
"Quiet Period" has a legal definition:
In United States securities law, a quiet period is a period of time in which companies refrain from communicating with investors to avoid unfairly disclosing material, non-public information to certain investors when the company has not yet publicly communicated this information.[1]

When a company is raising capital from the public, the quiet period has "historically [meant], a quiet period of time extended from the time a company files a registration statement with the SEC until SEC staff declared the registration statement effective. During that period, the federal securities laws limited what information a company and related parties can release to the public."[2] This is also called the cooling-off period or waiting period. Under the rules of the Securities Act of 1933, as modified June 29, 2005, electronic communications, including electronic road shows and information located on or hyperlinked to an issuer's website are also governed. The rules changes of June 29, 2005, also included various changes which "liberalize permitted offering activity and communications to allow more information" for certain qualifying organizations.[citation needed]

The quiet period also means the period starting late in the third month of each quarter and ending on the day a public company announces its quarterly results.[3]

The company sitting on unblinded clinical trial data is their choice. Yeas they can't hype the trial, especially if they know it is not positive -- that's stock fraud. Biotech want to get good news out fast so they can benefit from a higher stock price, sell more stock, attract partners, etc. Nobody sits on GOOD news. Instead NWBO has spend 18 months with the data burning cash, having to borrow money from vulture funds, the borrower of last resort. Certainly not a good sign. Especially after the Phase 3 interim data did not meet protocol endpoints. When Novocure met their interim endpoint, they stop the trial (for success) and had an expedited approval and got on the market fast. Again why would NWBO sit on good news for over 18 months?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News